Drug intelligence / Profile preview

V350A

Development stage: Phase 1
Lead developer: Merck
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V350A is a vaccine candidate developed using the MDX2201 ferritin nanoparticle vaccine platform. It is being investigated for the prevention of Epstein-Barr virus (EBV) infection. The drug is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and immunogenicity in healthy adults. The study sponsor is Merck & Co, and development involves OPKO Health’s subsidiary ModeX. The primary indication for V350A is infections caused by Epstein-Barr virus.

Targets

gp350 (Epstein-Barr virus glycoprotein 350)

Beyond the preview

Go deeper on V350A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V350A.

Explore the full profile